Literature DB >> 29171898

I had no other option: Women, electroconvulsive therapy, and informed consent.

Karen-Ann Clarke1, Margaret Barnes1, Dyann Ross2.   

Abstract

Electroconvulsive therapy (ECT) is a controversial procedure used in the management of depression. Whilst it may be administered under mental health legislation, it is usually given to people who voluntarily consent. At the practice level, the consent process for ECT requires a detailed explanation of the procedure. The person consenting must have capacity to make this decision, and consent must be given freely and without coercion. Research using a feminist narrative approach unexpectedly highlighted the issue of potential coercion in the context of explaining the procedure. In-depth interviews were used to understand seven women's accounts of deciding to receive ECT. A thematic analysis of their narratives uncovered a shared concern with how they consented to the treatment. Four subthemes were identified that related to the way in which they provided their consent: (i) 'Not enough information'; (ii) 'I had no other choice'; (iii) 'Just go along with it'; and (iv) 'Lacking capacity'. A consent process that includes elements of passive coercion and a lack of timely and appropriate information influences the way some women make decisions. These factors can disempower women at the point of decision-making. A practice shift is needed where women are enabled to have control over decisions. Further, there is a need to adhere more rigorously to noncoercive practice when obtaining consent.
© 2017 Australian College of Mental Health Nurses Inc.

Entities:  

Keywords:  capacity; consent; electroconvulsive therapy; feminist; women

Mesh:

Year:  2017        PMID: 29171898     DOI: 10.1111/inm.12420

Source DB:  PubMed          Journal:  Int J Ment Health Nurs        ISSN: 1445-8330            Impact factor:   3.503


  1 in total

1.  Recipients' experience with information provision for electroconvulsive therapy (ECT).

Authors:  A Coman
Journal:  BMC Psychiatry       Date:  2022-02-04       Impact factor: 3.630

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.